Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Apellis Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
October 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
October 22, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
October 16, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
September 25, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
September 20, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 29, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
August 08, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
July 18, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 09, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
June 28, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
June 10, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 24, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
May 14, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
April 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
April 23, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 11, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
APLS
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.